Bird (e.g., Chicken, Etc.) Patents (Class 800/19)
  • Patent number: 10555508
    Abstract: A transgenic non-human animal is provided. In certain embodiments, the animal comprises a genome comprising an immunoglobulin heavy chain locus comprising: a) a transcribed gene encoding a fusion protein comprising, from N-terminus to C-terminus: i. a scaffold comprising a first binding domain; and ii. a heavy chain constant region operably linked to the scaffold; wherein the scaffold is capable of specifically binding to a target in the absence of additional polypeptides; and b) a plurality of pseudogenes that are operably linked to the transcribed gene and that donate, by gene conversion, nucleotide sequence to the part of the transcribed gene that encodes the binding domain.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: February 11, 2020
    Assignee: CRYSTAL BIOSCIENCE INC.
    Inventor: William Don Harriman
  • Patent number: 10202578
    Abstract: The present Invention provides as avian cell in which the expression or activity of one or more of the following genes, or a homologue thereof: Chicken IFITM 1 (SEQ ID No. 1); Chicken IFITM2 (SEQ ID No. 2) and Chicken IFITM3 (SEQ ID No. 3) is reduced. The invention also provides methods for passaging viruses in avian cells, embryos and/or avian cell lines which have reduced expression of one or more IFITM genes and methods which involve investigating the sequence of one or more of the following genes, or a homologue thereof: Chicken IFITM1 (SEQ ID No. 1); Chicken IFITM2 (SEQ ID No. 2) and Chicken IFITM3 (SEQ ID No. 3).
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: February 12, 2019
    Assignee: THE PIRBRIGHT INSTITUTE
    Inventors: Mark Fife, Mark Gibson
  • Patent number: 10184107
    Abstract: An electric ooycte denuding device and an ooycte denuding method are provided. The electric oocyte denuding device includes an oocyte denuding pipette: a manipulating handle; and a drive module, a control module, a display module, a power module, a memory, a bulb, and/or a voice module, and/or a pressure sensor, and/or a control box, and/or a foot-operated switch controller, which form an integrated type or a separated type electric ooycte denuding device. A stepper motor provides the power for blowing and sucking to denude the granular cells surrounding an oocyte.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: January 22, 2019
    Assignee: HUNAN CHANGSHA AO FIGURE BIOLOGICAL TECHNOLOGY CO., LTD.
    Inventor: Jianjun Peng
  • Patent number: 9994865
    Abstract: The presently disclosed subject matter relates to compositions and methods directed to cancer theranostic nucleic acid constructs that permit simultaneous cancer-specific viral replication, expression of a diagnostic gene product, and expression of a therapeutic gene.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: June 12, 2018
    Assignees: The Johns Hopkins University, Virginia Commonwealth University
    Inventors: Paul B. Fisher, Swadesh K. Das, Mitchell E. Menezes, Devanand Sarkar, Martin G. Pomper
  • Patent number: 9835560
    Abstract: The invention relates to a method for the Raman spectroscopic, in ovo sex determination of fertilized and hatched birds' eggs (1), wherein the embryo, including the extra-embryonic structures, can move in the egg, and is not yet attached to the shell at the time of measuring.
    Type: Grant
    Filed: July 3, 2015
    Date of Patent: December 5, 2017
    Assignees: TECHNISCHE UNIVERSITAET DRESDEN, UNIVERSITAET LEIPZIG
    Inventors: Roberta Galli, Grit Preusse, Edmund Koch, Gerald Steiner, Maria-Elisabeth Krautwald-Junghanns, Thomas Bartels
  • Patent number: 9809642
    Abstract: A transgenic chicken comprising an inactivated heavy immunoglobulin gene and/or inactivated light chain immunoglobulin gene is provided, as well as cells and targeting vectors for making the same.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: November 7, 2017
    Assignee: Crystal Bioscience Inc.
    Inventors: Philip A. Leighton, William Don Harriman, Robert Etches
  • Patent number: 8993729
    Abstract: Transgenes encoding exogenous antibodies are stably integrated into donor cells and are present in the somatic tissue of chimeric birds. The transgenes encode exogenous antibodies and are preferably expressed in the oviduct for collection in the egg. Tissue specificity is provided by selecting the content of the transgene accordingly. Birds whose genome is comprised of trangene-derived exogenous antibody-encoding DNA express exogenous antibodies having desirable chemical properties with increased therapeutic utility compared to antibodies derived from bacterial expression systems.
    Type: Grant
    Filed: July 16, 2012
    Date of Patent: March 31, 2015
    Assignee: Synageva Biopharma Corp.
    Inventors: Lei Zhu, Wen Zhou, Robert J. Etches
  • Publication number: 20150082471
    Abstract: A sustained culture of isolated avian gonocytes is provided, as well as a method of making and using the same. A chimeric avian containing an isolated gonocyte and a transgenic avian produced using the chimeric avian are also provided. The cell and method may be employed to make, among other things, transgenic avian that produce a heterologous protein, e.g., a therapeutic protein.
    Type: Application
    Filed: September 16, 2014
    Publication date: March 19, 2015
    Inventors: Marie-Cecile van de Lavoir, Robert Etches
  • Publication number: 20150072064
    Abstract: The present invention relates to methods for transfecting cells. In particular, the present invention relates to methods of transfecting primordial germ cells in avians, and to methods of breeding avians with modified traits.
    Type: Application
    Filed: April 19, 2013
    Publication date: March 12, 2015
    Inventor: Scott Geoffrey Tyack
  • Patent number: 8962311
    Abstract: Method of culturing embryonic stem (ES) cells of avian origin includes the steps of: a) suspending ES cells originating from the blastoderm disk of fertilized un-incubated avian egg(s) in a basal culture medium supplemented with: insulin-like growth factor-1 (IGF-1) and ciliary neurotrophic factor (CNTF); and animal serum; and, optionally, at least one growth factor selected from among interleukin 6 (Il-6), interleukin 6 receptor (Il-6R), stem cell factor (SCF), fibroblast growth factor (FGF), leukemia inhibitory factor (LIF), interleukin 11 (Il-11), oncostatin and/or cardiotrophin; b) seeding the suspension of ES cells obtained in step a) on a layer of feeder cells and further culturing the ES cells for at least 2 to 10 passages; c) optionally, removing at least one growth factor selected from among SCF, FGF, Il-6, Il-6R, LIF, oncostatin, cardiotrophin and Il-11 from the culture medium; and d) further culturing the ES cells in the medium of step c) on a layer of feeder cells.
    Type: Grant
    Filed: August 9, 2007
    Date of Patent: February 24, 2015
    Assignee: Valneva
    Inventors: Isabelle Valarche, Luc Batard, Majid Mehtali, Fabienne Guehenneux
  • Publication number: 20150010593
    Abstract: The present invention provides genetically modified cells useful for viral replication and the production of viral vaccines.
    Type: Application
    Filed: January 10, 2013
    Publication date: January 8, 2015
    Inventors: Marciela Degrace, Nir Hacohen, Sagi Shapira, Liguo Wu
  • Publication number: 20150013025
    Abstract: Disclosed are materials and methods for creating customizable traits in animals. In the demonstration of the principle of the subject invention, a keratin-14 specific promoter is used with red fluorescent protein in the loxp cassette, dominant black (?G23) beta defensin 103 in the pigment cassette, and an SV40 (with intron) polyadenylation sequence. When Cre recombinase (or HTNCre) is applied to the animal's skin in a carrier base (e.g., lipid bilayers), fur is permanently genetically modified to turn black in the shape in which the HTNCre was applied.
    Type: Application
    Filed: May 7, 2014
    Publication date: January 8, 2015
    Inventor: JAMES WEST
  • Publication number: 20140363467
    Abstract: The present invention relates to the production of avian induced pluripotent stem cells from non-pluripotent somatic cells, including embryonic fibroblasts and adult somatic cells. In this method, avian (including quail or chicken) somatic cells are reprogrammed into a state closely resembling embryonic stem cells including the expression of key stem cell markers alkaline phosphatase, etc. by transfecting/transducing the non-stem cells with genes (preferably using a non-integrating vector as otherwise described herein or alternatively an integrating vector, such a lentiviral vector, retroviral vector or inducible lentiviral vector, among others) which express at least nanog, Lin28 and cMyc. In preferred aspects of the invention, the transfected/transduced vectors express nanog, Lin28, cMyc, Oct 4 (POU5F1 or PouV), SOX2 and KLF4. The induced stem cells which are produced contribute to all 3 germ layers, the trophectoderm and in certain aspects, the gonad in chimeric offspring.
    Type: Application
    Filed: December 9, 2013
    Publication date: December 11, 2014
    Applicant: University of Georgia Research Foundation, Inc.
    Inventors: Steven L. Stice, Franklin West, Yangqing Lu
  • Publication number: 20140359796
    Abstract: A genetically modified livestock animal, and methods of making and using the same, the animal comprising a genetic modification to disrupt a target gene selectively involved in gametogenesis, wherein the disruption of the target gene prevents formation of functional gametes of the animal. Animals that create progeny with donor genetics, and methods of making and using the same. Cells, and methods of making and using the cells, with a genetic modification to disrupt a target gene selectively involved in gametogenesis.
    Type: Application
    Filed: April 28, 2014
    Publication date: December 4, 2014
    Inventors: Scott C. Fahrenkrug, Daniel F. Carlson
  • Publication number: 20140329996
    Abstract: Transgenes encoding exogenous antibodies are stably integrated into donor cells and are present in the somatic tissue of chimeric birds. The transgenes encode exogenous antibodies and are preferably expressed in the oviduct for collection in the egg. Tissue specificity is provided by selecting the content of the transgene accordingly. Birds whose genome is comprised of transgene-derived exogenous antibody-encoding DNA express exogenous antibodies having desirable chemical properties with increased therapeutic utility compared to antibodies derived from bacterial expression systems.
    Type: Application
    Filed: March 25, 2014
    Publication date: November 6, 2014
    Applicant: SYNAGEVA BIOPHARMA CORP.
    Inventors: Lei Zhu, Wen Zhou, Robert J. Etches
  • Publication number: 20140317765
    Abstract: The invention relates to transgenic birds capable of producing chimeric immunoglobulins, with a combination of human and avian sequence, in their B cells. In some embodiments, the birds are chickens. When challenged with an antigen, the transgenic avians produce antigen-specific functional antibodies. The invention also relates to light chain immunoglobulin transgenes for making such transgenic avians, as well as methods and vectors for disrupting endogenous immunoglobulin loci in birds.
    Type: Application
    Filed: August 30, 2012
    Publication date: October 23, 2014
    Applicant: SYNAGEVA BIOPHARMA CORP.
    Inventors: Philip A. Leighton, Emily J. Cadera
  • Patent number: 8865462
    Abstract: A sustained culture of isolated avian gonocytes is provided, as well as a method of making and using the same. A chimeric avian containing an isolated gonocyte and a transgenic avian produced using the chimeric avian are also provided. The cell and method may be employed to make, among other things, transgenic avian that produce a heterologous protein, e.g., a therapeutic protein.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: October 21, 2014
    Assignee: Crystal Bioscience Inc.
    Inventors: Marie-Cecile van de Lavoir, Robert Etches
  • Publication number: 20140298503
    Abstract: Transgenic avians which produce proteins in their oviduct tissue having modified oligosaccharide structures and methods of making such avians are disclosed herein. The invention also includes the modified proteins produced in the transgenic birds.
    Type: Application
    Filed: April 1, 2013
    Publication date: October 2, 2014
    Applicant: Synageva BioPharma Corp.
    Inventor: Alex J. Harvey
  • Publication number: 20140298504
    Abstract: The present invention is transgenic chickens obtained from long-term cultures of avian PGCs and techniques to produce and transgenic birds derived from prolonged PGC cultures. In some embodiments, these PGCs can be transfected with genetic constructs to modify the DNA of the PGC, specifically to introduce a transgene encoding an exogenous protein. When combined with a host avian embryo by known procedures, those modified PGCs are transmitted through the germline to yield transgenic offspring. This invention includes compositions comprising long-term cultures of PGCs and offspring derived from them that are genetically modified.
    Type: Application
    Filed: March 7, 2014
    Publication date: October 2, 2014
    Inventors: Marie-Cecile Van de Lavoir, Philip A. Leighton
  • Publication number: 20140289880
    Abstract: The present invention is transgenic chickens obtained from long-term cultures of avian PGCs and techniques to produce and transgenic birds derived from prolonged PGC cultures. In some embodiments, these PGCs can be transfected with genetic constructs to modify the DNA of the PGC, specifically to introduce a transgene encoding an exogenous protein. When combined with a host avian embryo by known procedures, those modified PGCs are transmitted through the germline to yield transgenic offspring. This invention includes compositions comprising long-term cultures of PGCs that can be genetically modified by gene targeting, that can accept large amounts of foreign DNA and that contribute to the germline of recipient embryos.
    Type: Application
    Filed: March 7, 2014
    Publication date: September 25, 2014
    Inventors: Marie-Cecile Van de Lavoir, Philip A. Leighton
  • Publication number: 20140289881
    Abstract: The present disclosure provides methods and compositions relating to a polynucleotide comprising a dsRNA region that is complementary to a particular region of the NS1 gene segment in the influenza virus genome that targets a sequence comprising two overlapping reading frames, one encoding NS1 and the second encoding the NEP polypeptide. Thus, the polynucleotide of the invention is able to target two message RNAs and is effective at inhibiting the replication of influenza virus in a cell.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 25, 2014
    Inventors: Timothy James Doran, Scott Geoffrey Tyack
  • Publication number: 20140289879
    Abstract: A transgenic avian containing in its genome an exogenous nucleotide sequence which includes a promoter component and a vector with reduced promoter interference wherein the exogenous nucleotide sequence is integrated into the genome and the avian.
    Type: Application
    Filed: February 28, 2014
    Publication date: September 25, 2014
    Inventors: Alex J. Harvey, Jeffrey C. Rapp
  • Publication number: 20140255383
    Abstract: The present invention provides compositions comprising an isolated mixture of recombinant human NaGlu proteins in which a substantial amount of the NaGlu proteins in the mixture has increased levels of phosphorylated mannose that confer the proteins to be efficiently internalized into human cells. The present invention also provides methods of producing such mixture of NaGlu proteins, vectors used in transgenesis and expression, host cells harboring such vectors, and methods of isolating and purifying the mixture of NaGlu proteins. The invention further provides methods of treating NaGlu associated diseases.
    Type: Application
    Filed: October 11, 2012
    Publication date: September 11, 2014
    Inventors: Anthony Quinn, Markley C. Leavitt, Zhinan Xia, Joseph Victor Rutkowski
  • Publication number: 20140245465
    Abstract: An aim is to produce a suitable foreign protein in egg white in transgenic birds at levels equivalent to or higher than the expression levels achieved using an ovalbumin promoter or an actin promoter, and to reduce the great burden on birds by reducing the expression at sites other than the oviduct while achieving expression sufficient to predict the expression levels before the birds reach sexual maturity. Provided is a transgenic bird containing a nucleic acid base sequence in chromosome in a cell that forms the oviduct, the sequence containing: (a) an avian endoplasmic reticulum chaperone promoter; and (b) a nucleic acid base sequence encoding a suitable foreign protein, functionally linked to the promoter. Also provided is a method for producing a suitable foreign protein, including recovering the suitable foreign protein from the transgenic bird.
    Type: Application
    Filed: August 27, 2012
    Publication date: August 28, 2014
    Applicant: KANEKA CORPORATION
    Inventors: Kenji Kyogoku, Hiroyuki Watanabe
  • Publication number: 20140237633
    Abstract: The present invention is long-term cultures of avian PGCs and techniques to produce germline chimeric and transgenic birds derived from prolonged PGC cultures. In some embodiments, these PGCs can be transfected with genetic constructs to modify the DNA of the PGC, specifically to introduce a transgene encoding an exogenous protein. When combined with a host avian embryo by known procedures, those modified PGCs are transmitted through the germline to yield transgenic offspring. These germline chimeric birds do not have substantial contributions of PGC-derived phenotypes in somatic cells or tissues. This invention includes compositions comprising long-term cultures of PGCs that can be genetically modified by gene targeting, that can accept large amounts of foreign DNA and that contribute to the germline of recipient embryos.
    Type: Application
    Filed: January 24, 2014
    Publication date: August 21, 2014
    Inventors: Marie-Ceclie Van de Lavoir, Philip Albert Leighton
  • Publication number: 20140201858
    Abstract: The invention relates to organisms and compositions comprising one or more stem cells or one or more embryos, wherein the one or more stem cells or one or more embryos comprise one or more of the following mutations: (i) a deletion mutation; (ii) a knockout mutation; and/or (iii) an addition of a heterologous nucleic acid sequence; wherein the one or more mutations of (i), (ii), and/or (iii) are site-specific mutations caused by a Xanthomonas TAL nuclease (XTN). The invention also relates to method of mutating an embryo, iPS cell, stem cell, or more particularly a spermatogonial stem cell by exposing the nucleic acid sequence contained within such embryos or cell with a Xanthomonas TAL nuclease.
    Type: Application
    Filed: May 17, 2012
    Publication date: July 17, 2014
    Applicant: Transposagen Biopharmaceuticals, Inc
    Inventors: Eric M. Ostertag, John S. Crawford, J. Keith Joung
  • Publication number: 20140189898
    Abstract: The present invention provides a method of identifying an animal having a genotype associated with resistance to bacterial infection comprising the steps of: (a) providing a sample from said animal; (b) determining the alleles at one or more markers of the SAL1 locus to identify the genotype of the marker, wherein said SAL1 locus lies between 54.0 MB to 54.8 MB of chicken Chromosome 5 or an equivalent thereof; and (c) determining whether the genotype is a genotype associated with resistance to bacterial infection.
    Type: Application
    Filed: March 6, 2014
    Publication date: July 3, 2014
    Applicant: The Pirbright Institute
    Inventors: Mark Fife, Peter Kaiser, Nigel Salmon
  • Publication number: 20140123330
    Abstract: A genetically modified livestock animal comprising a genome that comprises inactivation of a neuroendocrine gene selective for sexual maturation, with the inactivation of the gene preventing the animal from becoming sexually mature. Methods of using, and processes of making, the animals are taught.
    Type: Application
    Filed: October 30, 2013
    Publication date: May 1, 2014
    Inventors: Daniel F. Carlson, Scott C. Fahrenkrug, Xavier Lauth
  • Patent number: 8703485
    Abstract: The invention relates to transgenic animals lacking endogenous Ig and capable of producing transgenic antibodies, as well as methods of making the same. The invention further relates to methods for producing transgenic antibodies in such animals, and transgenic antibodies so produced.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: April 22, 2014
    Assignee: OMT, Inc.
    Inventor: Roland Buelow
  • Publication number: 20140082759
    Abstract: A transgenic chicken comprising an inactivated heavy immunoglobulin gene and/or inactivated light chain immuno -well as globulin gene is provided, as we cells and targeting vectors for making the same.
    Type: Application
    Filed: May 23, 2012
    Publication date: March 20, 2014
    Applicant: Crystal Bioscience Inc.
    Inventors: Phil Leighton, William Don Harriman, Robert Etches
  • Publication number: 20140068797
    Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 6, 2014
    Applicants: UNIVERSITY OF VIENNA, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jennifer A. Doudna, Martin Jinek, Emmanuelle Charpentier, Krzysztof Chylinski, James Harrison Doudna Cate, Wendell Lim, Lei Qi
  • Publication number: 20140068796
    Abstract: A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region.
    Type: Application
    Filed: October 18, 2013
    Publication date: March 6, 2014
    Applicant: CRYSTAL BIOSCIENCE, INC.
    Inventors: William Don Harriman, Robert Etches, Phil Leighton
  • Publication number: 20140053287
    Abstract: This invention relates to polypeptides having aldolase activity, including pyruvate activity such as, without limitation, HMG and/or KHG aldolase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In some embodiments, the invention is directed to polypeptides having aldolase activity, including pyruvate activity such as, without limitation, HMG and/or KHG aldolase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The polypeptides in accordance with the invention can be used in a variety of pharmaceutical, agricultural and industrial contexts.
    Type: Application
    Filed: August 14, 2013
    Publication date: February 20, 2014
    Applicant: VERENIUM CORPORATION
    Inventors: David P. WEINER, Lishan ZHAO, Peter LUGINBUHL, Ellen BURKE, Toby H. RICHARDSON, Paula M. HICKS
  • Patent number: 8598409
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel ecdysone receptor/chimeric retinoid X receptor-based inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: December 3, 2013
    Assignee: Intrexon Corporation
    Inventors: Marianna Zinovievna Kapitskaya, Subba Reddy Palli
  • Patent number: 8592644
    Abstract: A transgenic animal is provided. In certain embodiments, the transgenic animal comprises a genome comprising: an immunoglobulin light chain locus comprising: a) a functional immunoglobulin light chain gene comprising a transcribed variable region encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of 2 to 5 different amino acids; and ii. a light chain framework; and, operably linked to the functional immunoglobulin light chain gene: b) a plurality of pseudogene light chain variable regions each encoding: i. light chain CDR1, CDR2 and CDR3 regions that are composed of the same 2 to 5 different amino acids as the CDRs of the functional gene; and ii. a light chain framework that is identical in amino acid sequence to the light chain framework of the transcribed variable region.
    Type: Grant
    Filed: August 11, 2010
    Date of Patent: November 26, 2013
    Assignee: Crystal Bioscience Inc.
    Inventors: William Don Harriman, Robert Etches, Phil Leighton
  • Patent number: 8563803
    Abstract: The invention includes isolating pharmaceutical proteins from avian hard shell eggs containing pharmaceutical proteins wherein the pharmaceutical proteins are exogenous to the egg.
    Type: Grant
    Filed: June 24, 2005
    Date of Patent: October 22, 2013
    Assignees: Synageva BioPharma Corp., The University of Georgia Research Foundation, Inc.
    Inventors: Robert D. Ivarie, Alex J. Harvey, Julie A. Morris, Guodong Liu, Jeffrey C. Rapp
  • Publication number: 20130276156
    Abstract: The present invention relates to the field of biotechnology or genetic engineering. More specifically, the present invention relates to a multiple inducible gene regulation system that functions within cells to simultaneously control the quantitative expression of multiple genes.
    Type: Application
    Filed: September 13, 2012
    Publication date: October 17, 2013
    Applicant: Intrexon Corporation
    Inventors: Tarlochan Singh DHADIALLA, Dean Ervin Cress, Glenn Richard Carlson, Robert Eugene Hormann, Subba Reddy Palli, Arthur John Kudla, Ronald Phillip Herzig, JR., Mohan Philip
  • Publication number: 20130276153
    Abstract: A transgenic avian containing in its genome an exogenous nucleotide sequence which includes a promoter component and a vector with reduced promoter interference wherein the exogenous nucleotide sequence is integrated into the genome and the avian.
    Type: Application
    Filed: January 22, 2013
    Publication date: October 17, 2013
    Inventors: Alex J. Harvey, Jeffrey C. Rapp
  • Publication number: 20130273021
    Abstract: The present invention provides a novel fusion polypeptide containing a catalytic portion of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.
    Type: Application
    Filed: March 11, 2011
    Publication date: October 17, 2013
    Applicant: SYNAGEVA BIOPHARMA CORP.
    Inventors: Anthony Quinn, Alex J. Harvey, Zhinan Xia
  • Patent number: 8519214
    Abstract: This invention provides for proteins which are expressed in the avian oviduct, packaged into eggs laid by the avian, then isolated.
    Type: Grant
    Filed: March 15, 2006
    Date of Patent: August 27, 2013
    Assignees: Synageva BioPharma Corp., The University of Georgia Research Foundation, Inc.
    Inventors: Robert D. Ivarie, Alex J. Harvey, Julie A. Morris, Guodong Liu, Jeffrey C. Rapp
  • Publication number: 20130219533
    Abstract: In some aspects, the invention provides compositions and methods for inhibiting viral infection. In some aspects, the invention provides compositions and methods useful for identifying antiviral compounds.
    Type: Application
    Filed: June 17, 2011
    Publication date: August 22, 2013
    Applicant: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Thijn R. Brummelkamp, Jan E. Carette
  • Publication number: 20130212722
    Abstract: Disclosed are materials and methods for creating customizable traits in animals. In the demonstration of the principle of the subject invention, a keratin-14 specific promoter is used with, red fluorescent protein in the loxp cassette, dominant black (?G23) beta defensin 103 in the pigment cassette, and an SV40 (with intron) polyadenylation sequence. When Cre recombinase (or HTNCre) is applied to the animal's skin in a carrier base (e.g., lipid bilayers), fur is permanently genetically modified to turn black in the shape in which it was applied.
    Type: Application
    Filed: February 15, 2013
    Publication date: August 15, 2013
    Applicant: MICE WITH HORNS, LLC
    Inventor: Mice With Horns, LLC
  • Publication number: 20130209436
    Abstract: The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of treating conditions associated with lysosomal acid lipase deficiency.
    Type: Application
    Filed: April 23, 2011
    Publication date: August 15, 2013
    Applicant: SYNAGEVA BIOPHARMA CORP.
    Inventors: Anthony Quinn, Alex J. Harvey
  • Patent number: 8507749
    Abstract: This invention provides vectors and methods for the stable introduction of exogenous nucleic acid sequences into the genome of a bird and for expressing said exogenous sequences to alter the phenotype of the bird or to produce desired proteins. In particular, transgenic chickens are produced which express exogenous sequences in their oviducts. Eggs which contain exogenous proteins are also produced.
    Type: Grant
    Filed: November 15, 2005
    Date of Patent: August 13, 2013
    Assignees: Synageva BioPharma Corp., The University of Georgia Research Foundation, Inc.
    Inventors: Robert D. Ivarie, Alex J. Harvey, Julie A. Morris, Guodong Liu, Jeffrey C. Rapp
  • Patent number: 8431770
    Abstract: Transgenic avians which produce proteins in their oviduct tissue having modified oligosaccharide structures and methods of making such avians are disclosed herein. The invention also includes the modified proteins produced in the transgenic birds.
    Type: Grant
    Filed: January 7, 2009
    Date of Patent: April 30, 2013
    Assignee: Synageva BioPharma Corp.
    Inventor: Alex J. Harvey
  • Publication number: 20130023653
    Abstract: Transgenes encoding exogenous antibodies are stably integrated into donor cells and are present in the somatic tissue of chimeric birds. The transgenes encode exogenous antibodies and are preferably expressed in the oviduct for collection in the egg. Tissue specificity is provided by selecting the content of the transgene accordingly. Birds whose genome is comprised of trangene-derived exogenous antibody-encoding DNA express exogenous antibodies having desirable chemical properties with increased therapeutic utility compared to antibodies derived from bacterial expression systems.
    Type: Application
    Filed: July 16, 2012
    Publication date: January 24, 2013
    Inventors: Lei Zhu, Wen Zhou, Robert J. Etches
  • Publication number: 20120331576
    Abstract: The use of interferon induced transmembrane protein 1, 2, or 3 (IFITM1, 2, or 3) as a viral restriction factor, and methods of using the same to produce virus, transgenic animals expressing exogenous IFITM1, 2, or 3, and methods of treating or inhibiting viral infections by targeting a gene identified herein
    Type: Application
    Filed: December 10, 2010
    Publication date: December 27, 2012
    Applicants: THE GENERAL HOSPITAL CORPORATION, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Abraham Brass, Stephen Elledge
  • Patent number: 8324447
    Abstract: The present invention relates to animal model systems comprising a chimera between an avian embryo and a mammalian organism. Specifically, chimeric model systems comprising normal, diseased or genetically transformed mammalian cells and tissues transplanted into avian embryos, and uses thereof for in vivo testing of drugs and therapeutic modalities are disclosed.
    Type: Grant
    Filed: June 28, 2005
    Date of Patent: December 4, 2012
    Assignees: Bar Ilan University, Medical Research Fund of Tel-Aviv Sourasky Medical Center
    Inventors: Ron Goldstein, Tamar Tennenbaum, Varda Deutsch
  • Publication number: 20120266265
    Abstract: This invention provides vectors and methods for the stable introduction of exogenous nucleic acid sequences into the genome of avians in order to express the exogenous sequences to alter the phenotype of the avians or to produce desired proteins. In particular, transgenic avians are produced which express exogenous sequences in their oviducts and which deposit exogenous proteins into their eggs. Avian eggs that contain exogenous proteins are encompassed by this invention. The instant invention further provides novel forms of interferon and erythropoietin which are efficiently expressed in the oviduct of transgenic avians and deposited into avian eggs.
    Type: Application
    Filed: June 24, 2011
    Publication date: October 18, 2012
    Inventors: Robert D. Ivarie, Alex J. Harvey, Julie A. Morris, Guodong Liu, Jeffrey C. Rapp
  • Patent number: 8283518
    Abstract: Methods and compositions for the administration of transposon-based vectors to the reproductive organs of animals and the creation of transgenic animals. Preferred methods involve administration of the transposon-based vectors to the lumen of the oviduct of an avian, expression of a vector derived transgene in the avian, and deposition of the resultant polypeptide in an egg. This invention allows for large amounts of protein to be deposited in the egg.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: October 9, 2012
    Assignees: TransGenRx, Inc., The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Richard K. Cooper, William C. Fioretti, Gary G. Cadd